XBiotech XBIT
NASDAQ XBIT
$2.21 +0.03 (+1.29%)
As of: Sep 30, 2026 · 2:35 PM EDT

XBiotech (XBIT) Current Deferred Revenue (2019 - 2020)

Updated

XBiotech's Current Deferred Revenue was $1.5 million in Q2 2020, unchanged from the prior quarter.

Analysis

XBiotech (XBIT) Current Deferred Revenue (2019 - 2020) Analysis & Trends

At the end of FY2019, Current Deferred Revenue at XBiotech came in at $4.5 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 XBiotech 66.46 Mn 66.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2020 1.50 Mn
Mar 31, 2020 1.50 Mn
Dec 31, 2019 4.50 Mn
API Access

XBiotech Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=XBIT&period=max&api_key=YOUR_API_KEY